<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Previous studies have shown that the interleukin-12 receptor beta2 (IL-12Rbeta2) gene is expressed in <z:mpath ids='MPATH_458'>normal</z:mpath> naive, germinal center and memory B cells but not in their malignant counterparts </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to investigate (i) whether the IL-12Rbeta2 gene is silenced in B-cell <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>) cells, and (ii) what the functional implications of such silencing for <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> are </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we show that although mature B cells expressed both chains of the IL-12R, <z:mpath ids='MPATH_458'>normal</z:mpath> pro-B and pre-B cells failed to express the IL-12Rbeta2 chain </plain></SENT>
<SENT sid="3" pm="."><plain>Similarly, <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> cells from pediatric pro-B, early pre-B, and <z:e sem="disease" ids="C1292769" disease_type="Neoplastic Process" abbrv="">pre-B ALL</z:e> (30 cases) did not express the IL-12Rbeta2 chain </plain></SENT>
<SENT sid="4" pm="."><plain>IL-12Rbeta2 gene silencing in <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> was found to depend on methylation of a CpG island in exon 1 </plain></SENT>
<SENT sid="5" pm="."><plain>Such methylation was not detected in <z:mpath ids='MPATH_458'>normal</z:mpath> early B cells that when differentiated into mature B cells expressed the IL-12Rbeta2 gene </plain></SENT>
<SENT sid="6" pm="."><plain>Detection of IL-12Rbeta2 mRNA and protein in the tumorigenic 697 pre-<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> cell line allowed to perform functional experiments in severe combined immunodeficient/nonobese diabetic mice receiving 697 cells with or without human recombinant IL-12 (hrIL-12) </plain></SENT>
<SENT sid="7" pm="."><plain>hrIL-12 administration reduced <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> through antiproliferative and proapoptotic rather than antiangiogenic, activities </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion, epigenetic silencing of the IL-12Rbeta2 gene represents a novel mechanism of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> escape for <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> cells </plain></SENT>
</text></document>